Recent News

• 07.29.2026 - Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones
• 07.28.2026 - Enlivex Announces $400,000,000 Private Placement
• 07.20.2026 - Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
• 07.13.2026 - Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
• 07.07.2026 - Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026
• 06.24.2026 - Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume
• 06.22.2026 - Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
• 06.15.2026 - Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis
• 06.02.2026 - ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026
• 06.01.2026 - Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026

Recent Filings

• 07.29.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.29.2026 - EX-99.1 EX-99.1
• 07.28.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.28.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.28.2026 - EX-99.1 EX-99.1
• 07.20.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.20.2026 - EX-99.1 EX-99.1
• 07.13.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.13.2026 - EX-99.1 EX-99.1
• 07.07.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]